Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.97% 7.45 7.20 7.70 7.60 7.45 7.60 154,860 12:32:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 20

Evgen Pharma Share Discussion Threads

Showing 8101 to 8124 of 8400 messages
Chat Pages: 336  335  334  333  332  331  330  329  328  327  326  325  Older
DateSubjectAuthorDiscuss
07/4/2021
13:43
could be that evgen is being looked at by big pharmas, maybe crossing the T's and dotting the i's, looks like a game changer imho.
dutch123
07/4/2021
10:08
08.49 added. can't beat cheap broccoli..
dutch123
07/4/2021
08:57
httPs://twitter.com/walbrookpr/status/1379704261567774724?s=21 Well done Walbrook, better late than never...
bumpa33
07/4/2021
08:53
Interesting that the company issued no caveats or cautionary interpretation in the rns.
bocker01
07/4/2021
08:34
Lol...well the sanctimoniuos self righteous know it all is on record that SFX-01 will never be approved for Covid/ARDS and one of his last posts on the old thread is a classic, and probably encouraged the weak and worried to sell their shares sub 8p, makes you wonder what his and his lab assistant motives were in closing down the old thread!!!??? . ;-) Nobbygnome - 14 Feb 2021 - 13:53:19 - 7222 of 7271 And just to say I will be posting later today on the Guild thread precisely why I think SFX-01 has little chance of working in SARS and why it didn't work in the SAH trial. However, I stress I think it stands a good chance of working in oncology inidications and other indications such as ME.
moneymunch
07/4/2021
08:28
Evgen Pharma: Johns Hopkins research further assesses the potential of company's drug to treat COVID-19 Scientists found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed coronavirus Work carried out by researchers at the world-famous Johns Hopkins in the US appears to underline the potential of Evgen Pharma PLC’s (LON:EVG) lead drug in battling Coronavirus (COVID-19). Researchers found that sulforaphane, the active ingredient in the company’s multi-purpose treatment, SFX-01, prevents virus-induced cell death sparked by variants of the SARS-CoV-2 virus and another unnamed Coronavirus. In addition, the Johns Hopkins team went on to demonstrate the drug inhibited toxicity to cells as a pre-treatment before inoculation while also acting “synergistically” with antiviral drug remdesivir. Results from the lab-based work formed the basis of a recent pre-print publication that was released before it was peer-reviewed “given the urgency of the current pandemic”. SFX-01 is being administered to treat people with severe COVID in the STAR clinical trial being carried out by scientists at Dundee University. An interim analysis of the first hundred patients in the STAR study is expected sometime this quarter. Of the Johns Hopkins update, Evgen chief executive, Huw Jones, said: “If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study.”
moneymunch
07/4/2021
08:28
funny - two weeks since any comment on the Guild thread, and just that idiot on the short thread. I’d have thought if one were genuinely interested in EVG the guild thread would be humming? Or maybe they were never really that interested and should’ve just set up another “We love SNG” thread instead.
bumpa33
07/4/2021
08:21
Good to see the company think this is sufficiently significant to RNS, sure the share price will get traded, but I’d hope the time to trade is drawing to a close.
bumpa33
07/4/2021
08:19
We just need the short term profit takers mopped UP now. Gla ;-)
moneymunch
07/4/2021
08:19
HodHasharon7 Apr '21 - 07:19 - 608 of 614 0 1 0 Feels very similar to the early SNG days! Imagine peaking at 100p today...... And for today’s stupid post!!!!
chesty1
07/4/2021
08:17
Lol, yep although it will be transformational UPside profit that he'll really want, which will be a reality on positive efficacy data from SFX-01's Covid/ARDS trial. Gl ;-) ps No doubt plenty of regrets from the pi's who were selling their shares sub 8p!!!???
moneymunch
07/4/2021
08:09
Bumpa should be on commission.
riggerbeautz
07/4/2021
08:05
On and UP!!! Gla ;-)
moneymunch
07/4/2021
07:45
Very good RNS EVG MXC also worth a look.
amaretto1
07/4/2021
07:28
Having taken up my rights plus extras I'll settle for 10p, 15p etc etc. Good RNS.G.
garth
07/4/2021
07:28
That would be amazing HH, but we probably need positive efficacy data from Prof Chalmers for such a rise.....but back to double figures would be very nice and more than fair value given Evgen's multiple prospects and potential, let alone the stunning endoresment on SFX-01's chances of success from John Hopkins University. Gl ;-)
moneymunch
07/4/2021
07:27
Decent rns evg Should touch 10p today on that
nico115
07/4/2021
07:19
Feels very similar to the early SNG days! Imagine peaking at 100p today......
hodhasharon
07/4/2021
07:16
Most definitely, and well done Huw, the John Hopkins University research was more than worthy of comment by RNS, which no doubt will increase interest to the wider market in SFX-01's potential in treating Covid/ARDS.....Exciting times as we now await Prof Chalmers interim efficacy assesment, which is likely to be delivered sooner rather than later. Gla ;-) " The data have been published before peer review given the urgency of the current pandemic."
moneymunch
07/4/2021
07:11
Hugely positive no?
awise355
07/4/2021
07:01
RNS Number : 5753U Evgen Pharma PLC 07 April 2021 Evgen Pharma Plc ("Evgen" or "the Company") Publication on sulforaphane in COVID-19 Recent pre-print publication shows in vitro and in vivo antiviral activity of sulforaphane against the virus responsible for COVID-19 Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome notes a recent pre-print publication from Johns Hopkins University, USA1. The publication demonstrates that sulforaphane, the active ingredient in SFX-01, prevents virus-induced cell death in vitro induced by several variants of the SARS-CoV-2 virus and another coronavirus. The paper goes on to demonstrate that the inhibition of SARS-CoV-2 cytotoxicity by sulforaphane occurs both when cells are pre-treated with sulforaphane and when sulforaphane is administered 24 hours after viral inoculation. The work also shows that sulforaphane acts synergistically with the antiviral drug remdesivir. The authors further established that the effects of sulforaphane, administered orally, were observed in vivo in a mouse model infected with the SARS-CoV-2 virus where reduction in both viral load and lung pathology were observed. The data have been published before peer review given the urgency of the current pandemic. Evgen's SFX-01 is a druggable, clinical grade medicine currently at the clinical trial stage containing synthetic sulforaphane in a stable complex. Dr Huw Jones CEO of Evgen commented: "We are pleased to note these findings from Johns Hopkins University. If the data continue to demonstrate efficacy after peer review, they underpin and support the hypothesis we are testing with the University of Dundee in the STAR COVID-19 clinical study. We anticipate receiving the outcome of the interim analysis of the first 100 patients completing the study during this second quarter of 2021."
moneymunch
Chat Pages: 336  335  334  333  332  331  330  329  328  327  326  325  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210515 21:38:44